Certara and NVIDIA Partner to Bring AI-Powered Autonomous Agents to Drug Development
Key Insights
Certara has partnered with NVIDIA (search) to integrate the BioNeMo Agent Toolkit into its AI-driven drug discovery and development platform.
The collaboration combines Certara's biosimulation software and regulatory expertise with NVIDIA (search)'s AI agents to computationally simulate human biology.
AI agents will function autonomously alongside biosimulation models, aiming to accelerate insight generation across the drug development continuum.
Certara has announced a strategic partnership with NVIDIA (search) aimed at enhancing its artificial intelligence platform for drug discovery and development. The collaboration centers on incorporating the NVIDIA BioNeMo Agent Toolkit into Certara's existing biosimulation infrastructure, creating a unified system that combines computational modeling, regulatory expertise, and specialized datasets with AI-driven autonomous agents.
The partnership seeks to bridge Certara's established biosimulation software with NVIDIA (search)'s cutting-edge AI capabilities, enabling AI agents to function autonomously in complement to traditional biosimulation models and human scientific expertise. This integration is designed to accelerate the drug development process by computationally simulating human biology and improving insight generation throughout the development continuum.
The NVIDIA (search) BioNeMo Agent Toolkit serves as the technological backbone of the collaboration, providing the framework for AI agents that deliver specialized insights tailored to life sciences applications. By unifying Certara's proprietary datasets and regulatory knowledge with these autonomous agents, the partnership aims to create a more seamless and efficient pathway from early-stage discovery through later phases of development.
The announcement underscores the growing role of artificial intelligence in pharmaceutical R&D, where computational approaches are increasingly being deployed to address the complexity and high attrition rates that characterize traditional drug development. Certara's biosimulation expertise, combined with NVIDIA (search)'s AI infrastructure, positions the collaboration as a potentially transformative force in how new medicines are discovered, tested, and brought to market.
Neither company disclosed specific financial terms of the partnership or detailed timelines for the initial deployment of the integrated platform.